HUP0203288A2 - Foszfodiészteráz VII inhibitor hatású pirrolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Foszfodiészteráz VII inhibitor hatású pirrolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0203288A2
HUP0203288A2 HU0203288A HUP0203288A HUP0203288A2 HU P0203288 A2 HUP0203288 A2 HU P0203288A2 HU 0203288 A HU0203288 A HU 0203288A HU P0203288 A HUP0203288 A HU P0203288A HU P0203288 A2 HUP0203288 A2 HU P0203288A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
phosphodiesterase vii
pyrrole derivatives
vii inhibitors
Prior art date
Application number
HU0203288A
Other languages
English (en)
Inventor
Hans Michael Eggenweiler
Michael Gassen
Rochus Jonas
Thomas Welge
Michael Wolf
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0203288A2 publication Critical patent/HUP0203288A2/hu
Publication of HUP0203288A3 publication Critical patent/HUP0203288A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

A találmány tárgya (1) általános képletű vegyületek - ahol R1 és R2jelentése egymástól függetlenül H, A, OA, SA vagy Hal; R3 jelentése Hvagy A; R4 jelentése A vagy NH2; R5 jelentése H, NH2, NHA vagy NA2; Ajelentése 1-10 szénatomos alkil-, alkenil-, cikloalkil- vagy alkilén-cikloalkil-csoport; Hal jelentése fluor-, klór-, bróm- vagy jódatom ésfiziológiailag elfogadható sói és/vagy szolvátjai foszfodiészteráz VIIinhibitorként. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre és alkalmazásukra is. Ó
HU0203288A 1999-11-04 2000-10-25 Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use HUP0203288A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953025A DE19953025A1 (de) 1999-11-04 1999-11-04 Pyrrolderivate als Phosphodiesterase VII-Hemmer
PCT/EP2000/010526 WO2001032618A1 (de) 1999-11-04 2000-10-25 Pyrrolderivate als phosphodiesterase vii-hemmer

Publications (2)

Publication Number Publication Date
HUP0203288A2 true HUP0203288A2 (hu) 2003-01-28
HUP0203288A3 HUP0203288A3 (en) 2003-12-29

Family

ID=7927861

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203288A HUP0203288A3 (en) 1999-11-04 2000-10-25 Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use

Country Status (22)

Country Link
US (1) US6737436B1 (hu)
EP (1) EP1230215B1 (hu)
JP (1) JP2003513070A (hu)
KR (1) KR20020063173A (hu)
CN (1) CN1382122A (hu)
AR (1) AR026351A1 (hu)
AT (1) ATE339403T1 (hu)
AU (1) AU782477B2 (hu)
BR (1) BR0015334A (hu)
CA (1) CA2389709C (hu)
CZ (1) CZ20021440A3 (hu)
DE (2) DE19953025A1 (hu)
ES (1) ES2272331T3 (hu)
HK (1) HK1049831A1 (hu)
HU (1) HUP0203288A3 (hu)
MX (1) MXPA02004440A (hu)
NO (1) NO20022125L (hu)
PL (1) PL355099A1 (hu)
RU (1) RU2002113750A (hu)
SK (1) SK5952002A3 (hu)
WO (1) WO2001032618A1 (hu)
ZA (1) ZA200204433B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
HU228316B1 (en) 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
ES2437755T3 (es) 2004-07-01 2014-01-14 Daiichi Sankyo Company, Limited Intermedios para derivados de tienopirazol que tienen actividad inhibitoria de PDE 7
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080260643A1 (en) 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA3069432A1 (en) 2017-07-12 2019-01-17 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE154827C (hu)
DD154827A1 (de) * 1980-11-28 1982-04-21 Karl Gewald Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen
CA2273836A1 (en) 1996-12-10 1998-06-18 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation

Also Published As

Publication number Publication date
DE50013473D1 (de) 2006-10-26
AR026351A1 (es) 2003-02-05
AU1387301A (en) 2001-05-14
HK1049831A1 (zh) 2003-05-30
NO20022125D0 (no) 2002-05-03
ES2272331T3 (es) 2007-05-01
DE19953025A1 (de) 2001-05-10
ZA200204433B (en) 2003-09-03
SK5952002A3 (en) 2002-09-10
CN1382122A (zh) 2002-11-27
BR0015334A (pt) 2002-07-09
EP1230215B1 (de) 2006-09-13
CZ20021440A3 (cs) 2002-07-17
WO2001032618A1 (de) 2001-05-10
RU2002113750A (ru) 2004-01-10
ATE339403T1 (de) 2006-10-15
JP2003513070A (ja) 2003-04-08
CA2389709C (en) 2009-02-10
CA2389709A1 (en) 2001-05-10
AU782477B2 (en) 2005-08-04
MXPA02004440A (es) 2004-09-10
PL355099A1 (en) 2004-04-05
EP1230215A1 (de) 2002-08-14
HUP0203288A3 (en) 2003-12-29
NO20022125L (no) 2002-05-03
US6737436B1 (en) 2004-05-18
KR20020063173A (ko) 2002-08-01

Similar Documents

Publication Publication Date Title
HUP0203288A2 (hu) Foszfodiészteráz VII inhibitor hatású pirrolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300909A2 (hu) NHE-3 inhibitor hatású 2-guanidino-4-aril-kinazolin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
YU57603A (sh) Inhibitori fosfodiesteraze 4
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
HUP0202450A2 (hu) N-heterociklusos származékok mint NOS inhibitorok
HUP0002353A2 (hu) IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
ATE356117T1 (de) Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität
DE69831499D1 (de) Inhibitoren des nukleosid-metabolismus
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
HUP0203245A2 (hu) Foszfodiészteráz VII-inhibitorként használható imidazopiridinszármazékok és ezeket tartalmazó gyógyszerkészítmények
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO5550439A2 (es) Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
HUP0104033A2 (hu) Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
AU3415599A (en) Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents
HUP0203422A2 (hu) Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
FI945581A (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
HUP0203187A2 (hu) Izoxazolszármazékok mint foszfodiészteráz VII inhibitorok és ezeket tartalmazó gyógyszerkészítmények
IL157216A0 (en) Crystalline forms of pyrimidine nucleoside derivatives and pharmaceutical compositions containing the same
HUP0202479A2 (hu) Indolszármazékok
UA71004C2 (uk) Похідні 1-трифторометил-4-гідрокси-7-піперидиніламінометилхроману
HUP0001010A2 (hu) Benzimidazol-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
ES2155655T3 (es) Compuestos de benzotiofeno, usos y formulaciones de los mismos.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees